

## PRESSRELEASE

Stockholm March 15, 2019

### **ADDvise Group receives order worth 2,7 MSEK - regulatory information**

ADDvise Group AB's (publ) subsidiary LabRum has received an order from a biotechnology company focusing on tomorrow's biopharmaceutical, to a value of 2,7 MSEK. The order relates to laboratory furniture for a newly built laboratory. Delivery is planned to Q2 2019.

#### **For further information, please contact:**

Rikard Akhtarzand, CEO  
+46 765-25 90 71  
rikard.akhtarzand@addvisigroup.se

#### **Important information:**

*This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on March 15, 2019 at 14:00 CET.*

#### **About ADDvise Group**

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at [www.addvisigroup.com](http://www.addvisigroup.com).